Exscientia (EXAI) Stock Forecast & Price Target

$5.27

+0.05 (+0.96%)

(As of 12:58 PM ET)

Exscientia - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 4 Analyst Ratings

Based on 4 Wall Street analysts who have issued ratings for Exscientia in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 4 have given a hold rating for EXAI.

Consensus Price Target

$7.00
32.83% Upside

High Forecast	$9.00
Average Forecast	$7.00
Low Forecast	$5.00

According to the 4 analysts' twelve-month price targets for Exscientia, the average price target is $7.00. The highest price target for EXAI is $9.00, while the lowest price target for EXAI is $5.00. The average price target represents a forecasted upside of 32.83% from the current price of $5.27.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$7.00	$7.00	$9.75	$13.00
Forecasted Upside	32.83% Upside	33.67% Upside	58.41% Upside	69.64% Upside

Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad)

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.

EXAI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EXAI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Exscientia Stock vs. The Competition

Type	Exscientia	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	34.10% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	Barclays 3 of 5 stars	P. Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00	+1.63%
8/9/2024	TD Cowen 4 of 5 stars	B. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/22/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Equal Weight ➝ Equal Weight	$7.00 ➝ $7.00	+65.09%
1/5/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$11.00 ➝ $9.00	+37.40%
7/21/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$13.00	+62.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:29 PM ET.

EXAI Forecast - Frequently Asked Questions

What is Exscientia's forecast for 2024?: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Exscientia is $7.00, with a high forecast of $9.00 and a low forecast of $5.00.
Should I buy or sell Exscientia stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EXAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EXAI, but not buy additional shares or sell existing shares.
Does Exscientia's stock price have much upside?: According to analysts, Exscientia's stock has a predicted upside of 33.67% based on their 12-month stock forecasts.
What analysts cover Exscientia?: Exscientia has been rated by research analysts at Barclays, and TD Cowen in the past 90 days.
Do Wall Street analysts like Exscientia more than its competitors?: Analysts like Exscientia less than other "medical" companies. The consensus rating for Exscientia is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EXAI compares to other companies.